Showing 1361-1370 of 2330 results for "".
- Secukinumab Phase III Data Confirm Significant Efficacy in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/secukinumab-phase-iii-data-confirm-significant-efficacy-in-patients-with-psoriatic-arthritis/2458858/Results from the Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in The New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) antagonist to demonstrate efficacy in a Phase III
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam com
- National Psoriasis Foundation's Patient Registry Begins Recruitinghttps://practicaldermatology.com/news/national-psoriasis-foundations-patient-registry-begins-recruiting/2458999/People with psoriasis and their health care providers will have the opportunity to participate in re
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101.
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- Actavis Announces Acanya Gel Patent Challenge Settlementhttps://practicaldermatology.com/news/20140512-actavis_announces_acanya_gel_patent_challenge_settlement/2459243/
- Innocutis Introduces Dexter the Dystrophic Nail to Educate Patientshttps://practicaldermatology.com/news/20140417-innocutis_introduces_dexter_the_dystrophic_nail_to_educate_patients/2459265/Innocutis launched an animated social media campaign to educate on the prevalence of nail dystrophy and Nuvail as a viable treatment option. The antagonist of healthy nails in what the company calls a “fun, light-hearted, social media campaign” is
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/